| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.18 | 5e-05 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.17 | 0.003 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.16 | 0.003 |